ライフサイエンスコーパス: multidrug resistance

1 within phylogroup D-that is associated with multidrug resistance.

2 ified harbinger mutations that often precede multidrug resistance.

3 ay help to reduce the use of antibiotics and multidrug resistance.

4 pecific therapeutics in the effort to combat multidrug resistance.

5 nfections that are difficult to treat due to multidrug resistance.

6 path leading to the emergence of high-level, multidrug resistance.

7 of tuberculosis incidence and prevalence of multidrug resistance.

8 ost critical mechanisms leading to bacterial multidrug resistance.

9 s, which may have important implications for multidrug resistance.

10 ibiotics for tackling the issue of bacterial multidrug resistance.

11 might be clinically relevant to the rise of multidrug resistance.

12 etics and contributing to the development of multidrug resistance.

13 pathway represents a linchpin in C. glabrata multidrug resistance.

14 valganciclovir, and a UL54 mutation confers multidrug resistance.

15 les in microbial pathogenesis, virulence and multidrug resistance.

16 ids as potential targets to fight pathogenic multidrug resistance.

17 ilome that were associated with plasmids and multidrug resistance.

18 ota makes it a potential reservoir of mobile multidrug resistance.

19 infections, with many strains demonstrating multidrug resistance.

20 association of baseline characteristics with multidrug resistance.

21 lthough all 3 epidemics were associated with multidrug resistance.

22 idence, and summarized clinical features and multidrug resistance.

23 idenced an ability to overcome cisplatin and multidrug resistance.

24 worldwide, with an increasing prevalence of multidrug resistance.

25 s resistant to TCS exhibited higher rates of multidrug resistance.

26 ddress the global health need and burgeoning multidrug resistance.

27 or roles in drug pharmacokinetics and cancer multidrug resistance.

28 ounds and have been implicated in conferring multidrug resistance.

29 gly rendered ineffective by rising bacterial multidrug resistance.

30 -negative bacterium with the highest rate of multidrug resistance.

31 nosocomial pathogen with a high incidence of multidrug resistance.

32 t options include minocycline in the case of multidrug resistance.

33 re mediated by increased copy numbers of the multidrug resistance 1 gene (pvmdr1) may select for mefl

34 und to be a poor substrate (>30 muM) for the multidrug resistance 1 protein, suggesting low likelihoo

35 -bound ABC transporter PfMDR1 (P. falciparum multidrug resistance 1 transporter).

36 Multidrug resistance-1 (MDR1) acts as a chemotherapeutic

37 c-finger nucleases to genetically modify the multidrug resistance-1 transporter PfMDR1 at amino acids

38 Deficiency of multidrug resistance 2 (mdr2), a canalicular phospholipi

39 Treatment of multidrug resistance 2 gene knockout (Mdr2(-/-) ) mice w

40 We have shown that partial hepatectomy in multidrug resistance 2 knockout (Mdr2(-/-) ) mice, a mod

41 Wild-type and multidrug resistance 2 knockout mice (9-11 weeks) were t

42 rosis, histamine secretion, and bile flow in multidrug resistance 2 knockout mice.

43 antly reduces FBP levels in HCC cells and in multidrug resistance 2-deficient mice that develop HCC d

44 and a high prevalence of clinically relevant multidrug resistance (252 [52%] of 485 samples), which v

45 Defects in multidrug resistance 3 gene (MDR3), which encodes the ca

46 n genes involved in bile disposition: ABCB4 (multidrug resistance 3) rs2302387 and ABCB11 [bile salt

47 e niche-adaptive accessory traits, including multidrug resistance; 3) the accessory genome of the meg

48 ve limited or no treatment options, owing to multidrug resistance(6).

49 The recent increase in multidrug resistance against bacterial infections has be

50 Increasing multidrug resistance among ExPEC strains constitutes a m

51 The increasing multidrug resistance among gram-negative uropathogens ne

52 inical success, followed by echinocandin and multidrug resistance among some Candida species, especia

53 Multidrug-resistance among E.coli causing device- and pr

54 st that the HpnN transporter is critical for multidrug resistance and cell wall remodeling in Burkhol

55 1 inhibitors, leading to further research on multidrug resistance and combination chemotherapy.

56 , respectively, and 18.3% displayed combined multidrug resistance and DCS; rates of azithromycin and

57 Among Salmonella Typhi, rates of multidrug resistance and decreased ciprofloxacin suscept

58 utic drugs, including temozolomide, reverses multidrug resistance and increases survival in glioblast

59 Emerging threats, including multidrug resistance and increasing urbanization in regi

60 binding cassette (ABCC) transporters mediate multidrug resistance and ion conductance regulation.

61 transporter (PfCRT) is a key contributor to multidrug resistance and is also essential for the survi

62 ia is the epicentre of Plasmodium falciparum multidrug resistance and is facing high rates of dihydro

63 belonging to the H58 haplotype often exhibit multidrug resistance and may have a fitness advantage re

64 ssess cancer stem cell properties, promoting multidrug resistance and metastasis.

65 addressed the causal association between HIV multidrug resistance and mortality, excluding factors on

66 mps like P-glycoprotein (P-gp, ABCB1) confer multidrug resistance and mutant ABC proteins are respons

67 ncrease in the number of plasmids conferring multidrug resistance and strain replacement by a resista

68 lic health problem owing to the emergence of multidrug resistance and the lack of broadly efficient v

69 eruginosa adapts to the CF lung, can develop multidrug resistance, and can form biofilms.

70 ed stemness to nonstem cancer cells, induced multidrug resistance, and enhanced the migration potenti

71 resistance, second-line injectable-resistant multidrug resistance, and extensive multidrug resistance

72 ppropriate antibacterial use contributing to multidrug resistance, and increased morbidity and mortal

73 Hypervirulence, multidrug resistance, and opportunism have been proposed

74 i) hypersensitivity sometimes converted into multidrug resistance; and (iii) resistance gains frequen

75 Multidrug resistance arising from the activity of integr

76 nofluorescence analyses confirmed that MRP3 (multidrug resistance associated protein 3), which was hi

77 Multidrug resistance-associated protein 1 (adenosine tri

78 Overexpression of plasma membrane multidrug resistance-associated protein 1 (MRP-1) in Ewi

79 ivered IgGs can inhibit the drug efflux pump multidrug resistance-associated protein 1 (MRP1) and the

80 cytometry and immunostaining have shown that multidrug resistance-associated protein 1 (MRP1) is prev

81 regulates the cell surface expression of the multidrug resistance-associated protein 1 (MRP1) transpo

82 on a known ATP-binding cassette transporter, multidrug resistance-associated protein 1 (MRP1), and fo

83 cluding permeability glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1).

84 P-Glycoprotein (P-gp, ABCB1), multidrug resistance-associated protein 1 (MRP1, ABCC1),

85 th respect to potency and selectivity toward multidrug resistance-associated protein 1 (MRP1, ABCC1).

86 breast cancer resistance protein (BCRP), and multidrug resistance-associated protein 2 (MRP2) at the

87 eval of the bile salt export pump (Bsep) and multidrug resistance-associated protein 2 (Mrp2) from th

88 1A1 (Oatp1a1), the hepatobiliary transporter multidrug resistance-associated protein 2 (Mrp2), and th

89 0 administration significantly induced renal multidrug resistance-associated protein 2 and 4, peroxis

90 malignant lesions, we aim to investigate the multidrug resistance-associated protein 4 (MRP4)-depende

91 CK19 also positively regulated multidrug resistance-associated protein 4 expression at

92 Multidrug resistance-associated protein-1 (MRP-1), an ac

93 d that androgen glucuronides are effluxed by multidrug resistance-associated proteins 2 and 3.

94 Inhibitors of TDF's apical multidrug-resistance-associated protein efflux-transport

95 at a member of the distinct Escherichia coli multidrug resistance B (EmrB) family is a primary export

96 In addition, tumors often develop multidrug resistance based on the cellular efflux of che

97 erfamily make a considerable contribution to multidrug resistance by catalysing efflux of myriad stru

98 ruginosa, MexAB-OprM plays a central role in multidrug resistance by ejecting various drug compounds,

99 Multidrug transporters prompt multidrug resistance by exporting different therapeutics

100 extrusion (MATE) transporters contribute to multidrug resistance by extruding different drugs across

101 Bacterial efflux pumps confer multidrug resistance by transporting diverse antibiotics

102 pound extrusion (MATE) transporters underpin multidrug resistance by using the H(+) or Na(+) electroc

103 tigated for treatment of cancers, especially multidrug resistance cancer.

104 resistance (SMR) family drive the spread of multidrug resistance cassettes among bacterial populatio

105 sed on a lapatinib induced inhibition of the multidrug-resistance efflux transporter ABCB1, which is

106 antifungal stewardship is critical to limit multidrug resistance emergence.

107 earch demonstrates that TCC can select for a multidrug resistance encoding gene in mixed community an

108 drug resistance, involving a combination of multidrug resistance, extended spectrum beta-lactamase p

109 o studies were performed in BDL rats and the multidrug resistance gene 2 knockout (Mdr2(-/-) ) mouse

110 Herein, using the mouse model of PSC (multidrug resistance gene 2 knockout), the hepatic knock

111 in administration on hepatic fibrosis in the multidrug resistance gene 2-knockout (Mdr2(-/-)) mouse m

112 However, the role of macrophage multidrug resistance gene MDR1 on intracellular M. tuber

113 e-spanning transporter PfMDR1 (P. falciparum multidrug resistance gene-1) as a determinant of parasit

114 Additionally, putative multidrug resistance genes (emrE) were found in YSLPV1 a

115 tetracycline resistance genes (manures) and multidrug resistance genes (greenhouse soils).

116 ation and T-cell activation while repressing multidrug resistance genes and cancer-related genes, the

117 on of ssa and transposable elements encoding multidrug resistance genes triggered the expansion of sc

118 of resistance to single drug classes and now multidrug resistance greatly hampers patient management.

119 Multidrug resistance has emerged in all 3 serovars and i

120 e infections worldwide, is rapidly acquiring multidrug resistance, hastening the need for selective n

121 Bacterial virulence and the spread of multidrug resistance have previously been linked to toxi

122 We found multidrug resistance in 33 (9%) of 361 patients.

123 misclassification and its ability to develop multidrug resistance in a single step, highlights the ch

124 lications for understanding the emergence of multidrug resistance in bacteria.

125 umps play a key role in inherent and evolved multidrug resistance in bacteria.

126 cs and toxic metabolites, thereby conferring multidrug resistance in bacterial pathogens and cancer c

127 red a nanoparticle mimic that both overcomes multidrug resistance in cancer cells and increases tumou

128 nsport protein is a major target to overcome multidrug resistance in cancer patients.

129 s key position, ABC transporters can mediate multidrug resistance in cancer therapy and their dysfunc

130 pporting the potential of CXL146 to overcome multidrug resistance in cancer treatment.

131 ansporter that was shown to confer low-level multidrug resistance in cancer.

132 specific ATP-dependent transporter linked to multidrug resistance in cancer; it plays important roles

133 eutics, could therefore be used to attenuate multidrug resistance in cancers.

134 s of several variants, efficacy in reversing multidrug resistance in cell culture, and biochemical as

135 Transcription factors MarR and MarA confer multidrug resistance in enteric bacteria by modulating e

136 , such as AcrB, make a major contribution to multidrug resistance in Gram-negative bacteria.

137 infections are hampered by the evolution of multidrug resistance in pathogens as well as the lack of

138 stromal cells can promote tumorigenesis and multidrug resistance in prostate or breast cancer cells.

139 superfamily (RND) efflux system on intrinsic multidrug resistance in Serratia marcescens.

140 Multidrug resistance in the E. coli isolates collected (

141 ssette family, is one of the major causes of multidrug resistance in tumors.

142 Firmicutes multidrug resistance inc18 plasmids encode parS sites an

143 Multidrug resistance, including to ceftriaxone, will pos

144 ecular mechanism of Pdr1 gene activation and multidrug resistance inhibition by iKIX1.

145 fferent cancer treatments with synergism and multidrug resistance inhibition, which has great potenti

146 Multidrug resistance is a global threat as the clinicall

147 herapeutic antibiotics; however, the rise in multidrug resistance is a growing threat to the utility

148 We propose that multidrug resistance is a multifactorial process and tha

149 Bacterial multidrug resistance is a significant health issue.

150 Moreover, as multidrug resistance is common among S. maltophilia isol

151 Multidrug resistance is common, and resistance to third-

152 Multidrug resistance is highly conserved in mammalian, f

153 Multidrug resistance is one major challenge to cancer tr

154 Although multidrug resistance is uncommon, increasing reports of

155 Multidrug-resistance is a substantial threat to global e

156 interaction of these agonists with the human multidrug resistance-linked transporter P-glycoprotein (

157 treatment enriched for strains that acquired multidrug resistance loci, encoding enzymes that confer

158 their parent compounds (e.g., circumventing multidrug resistance), making the dimerization concept h

159 Cancer cells can develop multidrug resistance (MDR) after prolonged exposure to c

160 bacterial resistance in hospitals, including multidrug resistance (MDR) and its association with seri

161 Multidrug resistance (MDR) attenuates the chemotherapy e

162 air, electron transfer, and a component of a multidrug resistance (MDR) efflux pump were concluded to

163 enine also displays off-target inhibition of multidrug resistance (MDR) efflux pumps.

164 he chemotherapeutic to overcome both BBB and multidrug resistance (MDR) glioma cells while providing

165 Multidrug resistance (MDR) in cancer arises from cross-r

166 e amplification release of DOX and overcomes multidrug resistance (MDR) in cancer cells, producing a

167 RP1), which are involved in the formation of multidrug resistance (MDR) in cancer chemotherapy.

168 expression of P-glycoprotein (Pgp) increases multidrug resistance (MDR) in cancer, which greatly impe

169 Multidrug resistance (MDR) is a major cause of failure i

170 Multidrug resistance (MDR) is a major impediment to canc

171 Multidrug resistance (MDR) is a major obstacle in cancer

172 f the promising strategies to overcome tumor multidrug resistance (MDR) is to deliver anticancer drug

173 This so-called multidrug resistance (MDR) may be reversed by selective,

174 Multidrug resistance (MDR) mediated by ATP-binding casse

175 Multidrug resistance (MDR) mediated by P-glycoprotein (P

176 Among the mechanisms of treatment failure is multidrug resistance (MDR) mediated by the ABCB1, ABCC1,

177 However, multidrug resistance (MDR) of cancer cells has remained

178 , which makes it a major player in mediating multidrug resistance (MDR) of cancer cells.

179 Multidrug resistance (MDR) of pathogens is an ongoing pu

180 The most common solid tumors show intrinsic multidrug resistance (MDR) or inevitably acquire such wh

181 Multidrug resistance (MDR) represents a global threat to

182 ay of treatment; however, the development of multidrug resistance (MDR) restricts the efficacy of cur

183 vels of GRP78 protein in cancer cells confer multidrug resistance (MDR) to therapeutic treatment.

184 lied this approach to a cellular reaction of multidrug resistance (MDR) transport, which was followed

185 lococcus aureus (MRSA) infection was 24% and multidrug resistance (MDR) was observed in 87% of the is

186 We reported the frequency of multidrug resistance (MDR)(resistance to ampicillin, cot

187 ) plays a crucial role in the development of multidrug resistance (MDR), a major obstacle for success

188 Conversely it is one of the main causes of multidrug resistance (MDR), being capable of effluxing m

189 Multidrug resistance (MDR), DCS, and combined MDR/DCS we

190 d monoresistance, rifampicin monoresistance, multidrug resistance (MDR), fluoroquinolone-resistant mu

191 r treatment approach, suffers seriously from multidrug resistance (MDR), generally caused by innate D

192 pe characterized by increased proliferation, multidrug resistance (MDR), invasion and metastasis.

193 molecule chemosensitizers can reverse cancer multidrug resistance (MDR), thus significantly improving

194 f RND-type efflux pumps is a major factor in multidrug resistance (MDR), which makes these pumps impo

195 Here, we analyzed the expression of 377 multidrug resistance (MDR)-associated genes in two indep

196 cer agents, leading to the phenomenon called multidrug resistance (MDR).

197 ins palliative because of the development of multidrug resistance (MDR).

198 glycoprotein (Pgp), a transporter conferring multidrug resistance (MDR).

199 al pathogen with one of the highest rates of multidrug resistance (MDR).

200 ic metabolism, including a decrease in ABCB1/multidrug resistance (MDR)1 p-glycoprotein (p-gp) expres

201 Increased prevalence of multidrug resistance (MDR; 94% compared to 60% in layers

202 We identified multidrug-resistance (MDR)-associated clade 4.3.1 as the

203 In addition, other molecules targeting multidrug-resistance mechanisms, such as efflux pumps, a

204 ce, we provide a framework for understanding multidrug resistance, mediated by analogous systems, acr

205 demic C difficile ribotypes characterised by multidrug resistance might depend on antibiotic selectio

206 igh HIV burden (Kenya), and a high burden of multidrug resistance (Moldova).

207 ibiotic regulations to prevent selection for multidrug resistance, new antibiotic classes, typhoid's

208 protein (Pgp) is an efflux pump important in multidrug resistance of cancer cells and in determining

209 and eukaryotes, with examples implicated in multidrug resistance of pathogens and cancer cells, as w

210 mily of efflux pumps have been implicated in multidrug resistance of this species complex.

211 Six out of the eight genes conferred multidrug resistance on KAM32, a drug hypersensitive str

212 established mutations could confer potential multidrug resistance on pH1N1 or HPAI H5N1 viruses.

213 ted with HIV-infected patients (P = .03) and multidrug resistance (OR, 6.6; 95% CI, 2.5-17.2; P < .00

214 of transcription factors is associated with multidrug resistance, our aim was to evaluate whether th

215 zoyl]benzoic acid, an inhibitor of the ABC-B/multidrug resistance/P-glycoprotein subfamily of transpo

216 nd the ATP-binding cassette subfamily (ABC-B/multidrug resistance/P-glycoprotein) transporters from l

217 morphisms that occur before the emergence of multidrug resistance, particularly katG p.Ser315Thr, int

218 orthologues, which are key regulators of the multidrug resistance pathway in Saccharomyces cerevisiae

219 a novel prophage repertoire, and an expanded multidrug resistance plasmid.

220 The rapid increase of multidrug resistance poses urgent threats to human healt

221 Multidrug resistance presents an obstacle in cancer trea

222 ABCB1 encodes Multidrug Resistance protein (MDR1), an ATP-binding cass

223 or (PXR) was observed together with ApoE and multidrug resistance protein 1 (MDR1) membrane transport

224 histochemical expression of bronchopulmonary multidrug resistance protein 1 (MRP1) and permeability g

225 Multidrug resistance protein 1 (MRP1) is an ABC exporter

226 eans to overcome resistance by silencing the multidrug resistance protein 1 (MRP1), before chemothera

227 ned against P-glycoprotein (P-gp, ABCB1) and multidrug resistance protein 1 (MRP1, ABCC1) to confirm

228 The ATP-binding cassette (ABC) transporter multidrug resistance protein 1 (MRP1/ABCC1) is responsib

229 iron release from cells via the transporter multidrug resistance protein 1 (MRP1/ABCC1).

230 mpicin-induced gene expression of CYP3A4 and multidrug resistance protein 1, as well as their respect

231 vity of two other major efflux transporters, multidrug resistance protein 2 and breast cancer resista

232 apical membrane to subapical puncta, whereas multidrug resistance protein 2 distributions were not ch

233 The multidrug resistance protein 2 knockout (Mdr2(-/)) mice

234 harmacological inhibition with JZL184 in the multidrug resistance protein 2 knockout (Mdr2(-/-) ) mou

235 ngiocyte proliferation and liver fibrosis in multidrug resistance protein 2 knockout (Mdr2KO) mice as

236 10 (apicoplast ribosomal protein S10), mdr2 (multidrug resistance protein 2) and crt (chloroquine res

237 information on the interaction of drugs with multidrug resistance protein 3 (MDR3) exists and its rol

238 hydroxysteroid sulfotransferase enzyme 2A1, multidrug resistance protein 3, and apical sodium-depend

239 drugs are either substrates or inhibitors of multidrug resistance protein 4 (MRP4), such as the anti-

240 In this study, we evaluated the role of multidrug resistance protein 4 (MRP4, or ABCC4), a nucle

241 signaling cascade (phospholipase A2, COX-2, multidrug resistance protein 4, and G-protein-coupled pr

242 tivation of TGFbeta, and upregulation of the multidrug resistance protein ABCG2.

243 y substrates for p-glycoprotein (ABCB1), the multidrug resistance protein known to facilitate transde

244 The multidrug resistance protein MRP1 is an ATP-binding cass

245 The multidrug resistance protein MRP1 is an ATP-driven pump

246 thiol/disulfide balance, greater extents of multidrug resistance protein-1 (MRP1) expression, and gr

247 ferase and the biliary phospholipid floppase multidrug-resistance protein 2 (Mdr2/Abcb4), resulting i

248 subfamily includes pumps, the long and short multidrug resistance proteins (MRPs), and an ATP-gated a

249 One family of these pumps, the small multidrug resistance proteins (SMRs), consists of protei

250 ucture of heterodimeric Thermus thermophilus multidrug resistance proteins A and B (TmrAB), which not

251 on antiparallel homo- or heterodimeric small multidrug resistance proteins and examine whether the in

252 n-regulation of miRNA downstream targets and multidrug resistance proteins and extent of apoptosis we

253 the expression of anti-apoptotic factors and multidrug resistance proteins.

254 With the rise of multidrug resistance, Pseudomonas aeruginosa infections

255 upregulation of a single gene, encoding the multidrug resistance pump ABCB1.

256 s of healthcare-associated infections (HAI); multidrug resistance reduces available options for antib

257 cobacteria, thus turning out to be promising multidrug-resistance-reversing agents.

258 to the case detection group (n=1439) and the multidrug-resistance risk group (n=314).

259 tuberculosis in the past 6 months or to the multidrug-resistance risk group if drugs for tuberculosi

260 in all analyses, whereas participants in the multidrug-resistance risk group were only included in an

261 To cope with the global bacterial multidrug resistance, scientific communities have devote

262 resistance (MDR), fluoroquinolone-resistant multidrug resistance, second-line injectable-resistant m

263 mental biocides, transporters from the small multidrug resistance (SMR) family drive the spread of mu

264 The small multidrug resistance (SMR) family provides an ideal syst

265 transport proteins are members of the small multidrug resistance (SMR) family that are composed of f

266 Multidrug-resistance status did not result in excess mor

267 cell response in melanoma cells resulting in multidrug resistance, termed induced drug-tolerant cells

268 Previously identified as a key mediator of multidrug resistance, the drug efflux behavior of P-glyc

269 As a contributor to multidrug resistance, the family of multidrug and toxin

270 e of such polymer-drug conjugates to reverse multidrug resistance through P-gp inhibition and to miti

271 The emergence of bacterial multidrug resistance to antibiotics threatens to cause r

272 Multidrug resistance to at least 3 additional antibiotic

273 operties of these two important molecules in multidrug resistance to chemotherapy.

274 ECC can rapidly acquire multidrug resistance to conventional antibiotics.

275 Multidrug resistance to current Food and Drug Administra

276 Multidrug resistance to rifampicin and dapsone was obser

277 esistance is uncommon, increasing reports of multidrug resistance to the azoles, echinocandins, and p

278 reened a known mutation(s) that could confer multidrug resistance to the currently approved NAIs osel

279 This study aimed to evaluate the prevalence, multidrug-resistance traits, PCR-detection of virulence,

280 loroquine resistance transporter (PfCRT) and multidrug resistance transporter (PfMDR1) can modulate t

281 , we sought to identify mutants of the small multidrug resistance transporter EmrE with reduced rates

282 EmrE is a small multidrug resistance transporter found in Escherichia co

283 de that resembles that of Cam binding to the multidrug resistance transporter MdfA.

284 and was a highly sensitive substrate of the multidrug resistance transporter P-glycoprotein (P-gp).

285 Inhibition of A(2B) AR signaling decreased multidrug resistance transporter protein expression, inc

286 ctionally decreases P-glycoprotein (P-gp), a multidrug resistance transporter.

287 Multidrug resistance transporters (MDRs) are best known

288 Multidrug resistance was common, highlighting a role for

289 Multidrug resistance was defined as resistance to 3 or m

290 progesterone as a modulator of P-gp-mediated multidrug resistance was established by esterification o

291 Multidrug resistance was found in 4% (9/203) of the isol

292 eptible to most antibiotics, indicating that multidrug resistance was not the dominant reason for pre

293 Multidrug resistance was present in 23.9% (84/351) of NT

294 Multidrug resistance was present in 68 (81.0%) of Salmon

295 We found that multidrug resistance was strongly associated with an EMT

296 micking the ability of Salmonella to reverse multidrug resistance, we constructed a gold nanoparticle

297 Forty-six TB cases, including 1 with multidrug resistance, were found in schoolchildren, for

298 n very young children and the development of multidrug resistance, which threatens efficacy of antimi

299 ry, and economic problems posed by bacterial multidrug resistance will not be found.

300 esistant multidrug resistance, and extensive multidrug resistance with resistance to both a fluoroqui